Etgo Er contains Etodolac. Etgo Er uses:
Carefully consider the potential benefits and risks of etodolac capsules and other treatment options before deciding to use etodolac capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.Etgo Er are indicated:1. For acute and long-term use in the management of signs and symptoms of the following:
2. For the management of acute pain
|Brand Name:||Etgo Er|
|Therapeutic Class:||Drugs for Osteoarthritis, Drugs used for Rheumatoid Arthritis, Non-steroidal Anti-inflammatory Drugs (NSAIDs)|
|Manufacturer:||BIOPHAR LIFESCIENCES PVT LTD|
|Last Updated:||2020-11-22 18:15:00|
Etgo Er contains Etodolac 600.0 Mg. Etgo Er doses
Carefully consider the potential benefits and risks of Etgo Er and other treatment options before deciding to use Etgo Er capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.
After observing the response to initial therapy with Etgo Er capsules, the dose and frequency should be adjusted to suit an individual patient's needs.
Dosage adjustment of Etgo Er is generally not required in patients with mild to moderate renal impairment. Etgo Er should be used with caution in such patients, because, as with other NSAIDs, they may further decrease renal function in some patients with impaired renal function.
Analgesia: The recommended total daily dose of Etgo Er for acute pain is up to 1000 mg, given as 200 to 400 mg every 6 to 8 hours. Doses of Etgo Er greater than 1000 mg/day have not been adequately evaluated in well-controlled clinical trials.
Osteoarthritis and Rheumatoid Arthritis: The recommended starting dose is 300 mg b.i.d., t.i.d., or 400 mg b.i.d., or 500 mg b.i.d. A lower dose of 600 mg/day may suffice for long-term administration. Physicians should be aware that doses above 1000 mg/day have not been adequately evaluated in well-controlled clinical trials.
In chronic conditions, a therapeutic response to therapy with Etgo Er is sometimes seen within one week of therapy, but most often is observed by two weeks. After a satisfactory response has been achieved, the patient's dose should be reviewed and adjusted as required.
The common side effects of Etgo Er involve the gastrointestinal system. It can cause abdominal pain, constipation, diarrhea, dyspepsia, flatulence, heartburn, nausea, GI ulcers, vomiting. Other events including abnormal renal function, anemia, dizziness, edema, elevated liver enzymes, headaches, increased bleeding time, pruritis, rashes, tinnitus etc.
Etgo Er is a non-steroidal anti-inflammatory drug (NSAID). It inhibits the formation of prostaglandins. The inhibition of prostaglandin synthesis observed with Etgo Er differs from that of other NSAIDs. Studies in human cell models have confirmed that Etgo Er is selective for the inhibition of COX-2. Experiments have shown Etgo Er to have marked anti-inflammatory activity, being more potent than several clinically established NSAIDs.
Etgo Er should be given with caution in patients with severe hepatic reactions, pre-existing asthma, fluid retention, hypertension or heart failure. If clinical sings and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g. eosinophilia, rash etc.), it should be discontinued.
Since Etgo Er is extensively protein-bound, it may be necessary to modify the dosage of other highly protein-bound drugs. The concomitant administration of Warfarin and Etgo Er should not require a dosage adjustment of either drug, however it has rarely led to prolonged prothrombin times, therefore caution should be exercised when Etgo Er is administered with Warfarin. Concomitant use of Ciclosporin, Methotrexate, Digoxin, or Lithium with NSAIDs may cause an increase in serum levels of these compounds and associated toxicities. Care should also be taken in patients treated with any of the following drugs as interactions have been reported in some patients: Anti-hypertensives, Mifepristone, other Analgesics, Corticosteroids and Quinolone Antibiotics.
Pregnancy: There are no adequate and well-controlled studies in pregnant women. It should be use in pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: It is not known whether Etgo Er is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue the drug taking into account the importance of the drug to the mother.
Etgo Er is contraindicated in patients with known hypersensitivity to Etgo Er. Etgo Er should not be given to patients who have experienced asthma, urticaria or other allergic-type reactions after taking Aspirin or other NSAIDs.
Symptoms following acute NSAID overdose are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain which are generally reversible with supportive care.
Store at a cool and dry place protected from light & moisture. Keep out of reach of children.
Etgo Er Tablet price in India 170